Page last updated: 2024-08-21

arsenic trioxide and Cancer of Endometrium

arsenic trioxide has been researched along with Cancer of Endometrium in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (50.00)29.6817
2010's0 (0.00)24.3611
2020's2 (50.00)2.80

Authors

AuthorsStudies
Fujii, K; Fujii, N; Maeda, Y; Matsuoka, H; Matsuoka, KI; Nakamura, K; Nishimori, H; Sugiura, H1
Cai, H; Li, X; Wang, J1
Bae-Jump, VL; Boggess, JF; Gehrig, PA; Zhou, C1
Bae-Jump, V; Boggess, JF; Gehrig, PA; Zhou, C1

Reviews

1 review(s) available for arsenic trioxide and Cancer of Endometrium

ArticleYear
Arsenic trioxide in the treatment of platinum-resistant recurrent endometrial cancer: a case report and literature review.
    Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology, 2020, Volume: 40, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Arsenic Trioxide; Endometrial Neoplasms; Female; Humans; Neoplasm Recurrence, Local

2020

Other Studies

3 other study(ies) available for arsenic trioxide and Cancer of Endometrium

ArticleYear
Successful Treatment of Acute Promyelocytic Leukemia Complicated with Endometrial Cancer by Arsenic Trioxide.
    Acta medica Okayama, 2021, Volume: 75, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Arsenic Trioxide; Endometrial Neoplasms; Female; Humans; Leukemia, Promyelocytic, Acute

2021
Arsenic trioxide (As2O3) inhibits expression of estrogen receptor-alpha through regulation of the mitogen-activated protein kinase (MAPK) pathway in endometrial cancer cells.
    Reproductive sciences (Thousand Oaks, Calif.), 2008, Volume: 15, Issue:10

    Topics: Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Endometrial Neoplasms; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Oxides

2008
Induction of apoptosis and inhibition of telomerase activity by arsenic trioxide (As2O3) in endometrial carcinoma cells.
    Gynecologic oncology, 2007, Volume: 105, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Growth Processes; Cell Line, Tumor; Dose-Response Relationship, Drug; Endometrial Neoplasms; Female; Flow Cytometry; Humans; Oxides; RNA, Messenger; Telomerase

2007